These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23122783)

  • 1. Primary systemic treatment of breast-cancer brain metastases.
    Bartsch R; Preusser M
    Lancet Oncol; 2013 Jan; 14(1):8-9. PubMed ID: 23122783
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain metastases from HER2-positive breast cancer.
    Susheela SP; Revannasiddaiah S; Madhusudhan N; Basavalingaiah A
    Lancet Oncol; 2013 Jan; 14(1):e3. PubMed ID: 23276370
    [No Abstract]   [Full Text] [Related]  

  • 3. Brain metastases from HER2-positive breast cancer.
    Nieder C
    Lancet Oncol; 2013 Jan; 14(1):e2-3. PubMed ID: 23276368
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain metastases from HER2-positive breast cancer - authors' reply.
    Bachelot T; Cropet C; Diéras V; Jimenez M; Campone M
    Lancet Oncol; 2013 Jan; 14(1):e3-4. PubMed ID: 23276371
    [No Abstract]   [Full Text] [Related]  

  • 5. For breast cancer patients with brain mets, new drug combo may be option.
    Oncology (Williston Park); 2012 Dec; 26(12):1209, 1212. PubMed ID: 23413603
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete response of brain metastases originating in breast cancer to capecitabine therapy.
    Siegelmann-Danieli N; Stein M; Bar-Ziv J
    Isr Med Assoc J; 2003 Nov; 5(11):833-4. PubMed ID: 14650117
    [No Abstract]   [Full Text] [Related]  

  • 7. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
    Bergen ES; Berghoff AS; Rudas M; Preusser M; Bartsch R
    Anticancer Drugs; 2015 Jun; 26(5):579-81. PubMed ID: 25714248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
    Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
    Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
    Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
    Fujita Y; Mizuta N; Sakaguchi K; Nakatsukasa K; Imai A; Umeda Y; Hamaoka A; Morita M; Shouji M; Goto M; Taguchi T
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1699-702. PubMed ID: 23152022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
    Abboud M; Saghir NS; Salame J; Geara FB
    Breast J; 2010; 16(6):644-6. PubMed ID: 21070441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
    Mutlu H; Büyükçelik A; Akça Z; Erden A
    J Oncol Pharm Pract; 2015 Feb; 21(1):72-3. PubMed ID: 24154651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
    Sakaguchi K; Mizuta N; Imai A; Nakatsukasa K; Taguchi T
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):261-3. PubMed ID: 22333639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.
    Sini V; Menghi A; Cursano MC; Mandolini PL; Lanza R
    Tumori; 2013; 99(6):273e-7e. PubMed ID: 24503802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
    Sato T; Nakagawa T; Kuwayama T; Oda G; Sugimoto H; Ishiba T; Sugihara K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2180-2. PubMed ID: 22202322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
    Cameron D
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
    [No Abstract]   [Full Text] [Related]  

  • 17. NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
    Pownall M
    BMJ; 2010 Jun; 340():c3145. PubMed ID: 20543014
    [No Abstract]   [Full Text] [Related]  

  • 18. [Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
    Nozoe T; Nozoe E; Iguchi T; Ito S; Ohga T; Koga T; Ezaki T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):907-8. PubMed ID: 23863733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug development in the targeted therapy era.
    Paoletti P
    J Clin Oncol; 2008 Aug; 26(22):3815-6. PubMed ID: 18669476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.